Zymeworks Inc Stock News

VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced

After over a decade of smooth sailing, stocks have been exceptionally turbulent for the past three years. Rising rates, high inflation, recession fears – you name it, and the bears have used it to m

Zymeworks Inc. (NASDAQ:ZYME ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Shrinal Inamdar – Director-Investor Relations Chris Astle – Senior Vice President an

VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced

VANCOUVER, British Columbia, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced

Zymeworks is a biotech company focused on developing therapies for hard-to-treat cancers. Its lead product, zanidatamab, has shown promising results in clinical trials and has been partnered with larg

Investors always hope to buy low and sell high. In order to do so, it's necessary to identify stocks that are undervalued.

Zymeworks Inc. (NASDAQ:ZYME ) Q2 2023 Earnings Call August 10, 2023 4:30 PM ET Company Participants Diana Papove - Director of Corporate Communications Chris Astle - Senior Vice President and Chief Fi

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.97 per share a year ago.

VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced

When dealing with the best small-cap stocks to buy, investors effectively absorb higher risk for the possibility of substantive rewards. Even better, these rewards can come in quickly, enabling those

ANGI, SFIX, ZVIA, ZYME and HOWL have been added to the Zacks Rank #1 (Strong Buy) List on July 26, 2023.

VANCOUVER, British Columbia, July 19, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced

Best biotech stocks represents a concept that, no matter what, the market cycle fundamentally delivers relevance. Now, let me back up by stating that no individual company offers a guarantee of succes

VANCOUVER, British Columbia, July 03, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced